Nine Diagnostics has been selected for the Spring 2026 cohort of the Drive Accelerator, a national program run by SCbio in partnership with MassBio, specifically supporting early-stage biomarker and diagnostics companies using machine learning and advanced measurement science to redefine earlier cancer detection, patient stratification, and treatment decisions.
Drive was launched in 2022 as a joint initiative to support scientific founders and early-stage life sciences companies at the intersection of translational science and commercial development. Since its founding, Drive has supported 59 early-stage companies that have collectively raised $175 million in funding and created nearly 100 jobs. The program is entirely equity-free, and participation includes access to a structured eight-week curriculum, a dedicated mentor advisory board, and curated introductions to industry partners and investors.
The Spring 2026 cohort was announced on March 31, 2026, with eleven companies selected, eight of them Massachusetts-based. Nine Diagnostics was selected for the Biomarkers and Diagnostics track, led by SCbio, which was designed for companies using machine learning and high-performance computing to develop biomarkers, diagnostics, and tests that stratify patients, predict disease progression, or accelerate therapeutic selection. Curriculum partners for the track include Eli Lilly and LabCorp, providing participating companies with direct access to decision-makers across the pharmaceutical and diagnostics sectors.
For Nine Diagnostics, Drive provides structured engagement at a stage where translating scientific capability into a clinical deployment pathway requires deep connections with commercial partners, payers, and diagnostic infrastructure providers. The company’s AI-enabled multi-omic nanosensor platform generates molecular fingerprints that combine proteomic, metabolomic, and lipidomic information alongside patient clinical context, and applies machine learning to identify disease-relevant patterns without requiring prior knowledge of which biomarkers matter. Drive’s network is well-suited to accelerate the strategic introductions that will be central to the company’s commercialization pathway.
The Biomarkers and Diagnostics track was specifically designed to give diagnostic and biomarker companies access to the commercial infrastructure, talent networks, and strategic partnerships needed to accelerate real-world impact, making it a well-matched environment for Nine Diagnostics at its current stage of development.
Drive participation adds to Nine Diagnostics’ growing set of accelerator and ecosystem engagements, alongside the Merck Digital Sciences Studio and the ACS BrightEdge Entrepreneurs Program, through which the company has been building visibility and strategic relationships across the precision diagnostics landscape.
Read the full Spring 2026 cohort announcement from MassBio and SCbio.
About Nine Diagnostics
Nine Diagnostics is an AI-enabled multi-omic nanosensor company advancing precision medicine. The platform simultaneously captures proteomic, metabolomic, and lipidomic signals alongside patient clinical context to generate a multi-omic fingerprint, using machine learning to identify disease-relevant patterns without requiring prior knowledge of which biomarkers matter. This enables pre-treatment patient stratification, on-treatment response monitoring, and post-treatment minimal residual disease detection. Founded by Freddy T. Nguyen, MD, PhD (CEO), Daniel A. Heller, PhD (CSO), and Mijin Kim, PhD (Scientific Advisor), Nine Diagnostics is based in Cambridge, Massachusetts.